In prior phase II trials, survodutide (BI 456906), a once-weekly dual GLP-1R/GCGR agonist, has shown significant efficacy in reducing body weight and hyperglycemia in individuals with obesity and/or T2DM [74,75,76,77]. Here, GCGR is linked to obesity disorder.